Redefining the Viral Reservoirs That Prevent HIV-1 Eradication

Overview

Journal Immunity

Publisher Cell Press

Specialty Allergy & Immunology

Date 2012 Sep 25

PMID 22999944

Citations 262

Authors

Evelyn Eisele

Robert F Siliciano

Affiliations

Soon will be listed here.

Abstract

This Perspective proposes definitions for key terms in the field of HIV-1 latency and eradication. In the context of eradication, a reservoir is a cell type that allows persistence of replication-competent HIV-1 on a timescale of years in patients on optimal antiretroviral therapy. Reservoirs act as a barrier to eradication in the patient population in which cure attempts will likely be made. Halting viral replication is essential to eradication, and definitions and criteria for assessing whether this goal has been achieved are proposed. The cell types that may serve as reservoirs for HIV-1 are discussed. Currently, only latently infected resting CD4(+) T cells fit the proposed definition of a reservoir, and more evidence is necessary to demonstrate that other cell types, including hematopoietic stem cells and macrophages, fit this definition. Further research is urgently required on potential reservoirs in the gut-associated lymphoid tissue and the central nervous system.

Citing Articles

Cannabis Use in HIV: Impact on Inflammation, Immunity and the Microbiome.

Langat R, Chakrawarti A, Klatt N Curr HIV/AIDS Rep. 2025; 22(1):19.

PMID: 39984806 DOI: 10.1007/s11904-025-00729-0.

Inhibition of TIGIT on NK cells improves their cytotoxicity and HIV reservoir eradication potential.

Wang Y, Li Y, Chen J, Guo C, Yu X, Zhang Z mBio. 2025; 16(3):e0322624.

PMID: 39918313 PMC: 11898710. DOI: 10.1128/mbio.03226-24.

Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.

Chen W, Berkhout B, Pasternak A Curr HIV/AIDS Rep. 2025; 22(1):15.

PMID: 39903363 PMC: 11794352. DOI: 10.1007/s11904-025-00723-6.

The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection.

Murzin A, Elfimov K, Gashnikova N Pathogens. 2025; 14(1).

PMID: 39860976 PMC: 11768375. DOI: 10.3390/pathogens14010015.

Persistent elite controllers as the key model to identify permanent HIV remission.

Gasca-Capote C, Ruiz-Mateos E Curr Opin HIV AIDS. 2025; 20(2):165-171.

PMID: 39773856 PMC: 11809733. DOI: 10.1097/COH.0000000000000907.

References

Nickle D, Jensen M, Shriner D, Brodie S, Frenkel L, Mittler J . Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol. 2003; 77(9):5540-6. PMC: 153940. DOI: 10.1128/jvi.77.9.5540-5546.2003. View

Varatharajan L, Thomas S . The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009; 82(2):A99-109. PMC: 2678986. DOI: 10.1016/j.antiviral.2008.12.013. View

Strain M, Gunthard H, Havlir D, Ignacio C, Smith D, Leigh-Brown A . Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003; 100(8):4819-24. PMC: 153639. DOI: 10.1073/pnas.0736332100. View

Arfi V, Riviere L, Jarrosson-Wuilleme L, Goujon C, Rigal D, Darlix J . Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol. 2008; 82(13):6557-65. PMC: 2447095. DOI: 10.1128/JVI.02321-07. View

Shan L, Yang H, Rabi S, Bravo H, Shroff N, Irizarry R . Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011; 85(11):5384-93. PMC: 3094997. DOI: 10.1128/JVI.02536-10. View

Farnet C, Haseltine W . Circularization of human immunodeficiency virus type 1 DNA in vitro. J Virol. 1991; 65(12):6942-52. PMC: 250802. DOI: 10.1128/JVI.65.12.6942-6952.1991. View

Blackard J . HIV compartmentalization: a review on a clinically important phenomenon. Curr HIV Res. 2012; 10(2):133-42. DOI: 10.2174/157016212799937245. View

Iwasaki H, Akashi K . Myeloid lineage commitment from the hematopoietic stem cell. Immunity. 2007; 26(6):726-40. DOI: 10.1016/j.immuni.2007.06.004. View

Kieffer T, Kwon P, Nettles R, Han Y, Ray S, Siliciano R . G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol. 2005; 79(3):1975-80. PMC: 544145. DOI: 10.1128/JVI.79.3.1975-1980.2005. View

10.

Gonzalez-Scarano F, Martin-Garcia J . The neuropathogenesis of AIDS. Nat Rev Immunol. 2005; 5(1):69-81. DOI: 10.1038/nri1527. View

11.

Alkhatib G, Combadiere C, Broder C, Feng Y, Kennedy P, Murphy P . CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996; 272(5270):1955-8. DOI: 10.1126/science.272.5270.1955. View

12.

Evering T, Mehandru S, Racz P, Tenner-Racz K, Poles M, Figueroa A . Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012; 8(2):e1002506. PMC: 3271083. DOI: 10.1371/journal.ppat.1002506. View

13.

Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler J . Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999; 354(9192):1782-5. DOI: 10.1016/S0140-6736(99)02035-8. View

14.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

15.

Bailey J, Williams T, Siliciano R, Blankson J . Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 2006; 203(5):1357-69. PMC: 2121215. DOI: 10.1084/jem.20052319. View

16.

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

17.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

18.

Contreras X, Schweneker M, Chen C, McCune J, Deeks S, Martin J . Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009; 284(11):6782-9. PMC: 2652322. DOI: 10.1074/jbc.M807898200. View

19.

Mansky L, Temin H . Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995; 69(8):5087-94. PMC: 189326. DOI: 10.1128/JVI.69.8.5087-5094.1995. View

20.

Ruff C, Ray S, Kwon P, Zinn R, Pendleton A, Hutton N . Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002; 76(18):9481-92. PMC: 136462. DOI: 10.1128/jvi.76.18.9481-9492.2002. View